Form 4: Palisade Bio CEO John Finley Reports Stock Transactions

CEO John Finley reports the vesting of restricted stock units and subsequent tax withholding, affecting his beneficial ownership of Palisade Bio stock.

Summary

• On May 6, 2024, Palisade Bio CEO John Finley reported transactions involving the vesting and settlement of restricted stock units (RSUs).
• These RSUs were granted on June 8, 2023, and November 21, 2023.
• A portion of the vested shares were withheld to cover tax obligations.
• Finley's direct ownership of common stock increased due to the vesting of RSUs, but decreased slightly due to the tax withholding.
• Finley also indirectly owns shares through FCW Investments, LLC, where he is the managing member.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports routine stock transactions related to executive compensation.

Positives

• The vesting of RSUs indicates that Finley is meeting the conditions of his equity compensation plan.

Future Outlook

An additional 1,622 and 2,111 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date of June 8, 2023, and November 21, 2023, respectively, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions have a minor impact on shareholders, reflecting changes in insider ownership.

Key Dates

Keywords

Palisade Bio, John Finley, restricted stock units, RSUs, beneficial ownership, Form 4, insider trading, equity compensation, vesting, tax withholding